RocRock Biotech

RocRock Biotech is a clinical-stage biotechnology company focused on developing next-generation Rho-associated protein kinase 2 (ROCK2) inhibitors for autoimmune and inflammatory diseases. The company was founded by prominent immunologists Dr. Dan Littman and Dr. Richard Flavell to exploit the therapeutic potential of the ROCK2 pathway in modulating Th17 and Treg cell balance. Its lead candidate, RR-101, is a highly selective oral small molecule designed to treat conditions such as chronic graft-versus-host disease and systemic sclerosis. By targeting ROCK2, RocRock aims to provide potent anti-fibrotic and anti-inflammatory effects while maintaining a favorable safety profile compared to non-selective inhibitors. The company is backed by leading life science investors, including OrbiMed, and is headquartered in New York.